Parkinson's disease (PD) is diagnosed on the basis of characteristic motor signs following clinical examination, and treatment has been overwhelmingly focused upon motor rather than non-motor symptoms until recently. Early and accurate detection of PD is considered desirable, with major research initiatives presently focused upon identifying and validating clinical batteries and biomarkers to this end. However, with increased appreciation of the occurrence of non-motor symptoms, and development of sophisticated biomarker methodology, it now seems possible to address risk assessment and diagnosis earlier in the course of the disease. The term 'Parkinson's associated risk syndrome' (PARS) has been coined to describe individuals at risk of developing PD, 1 and it is proposed that non-motor symptoms-for example, olfactory dysfunction, autonomic instability, constipation, and rapid eye movement (REM) sleep behavior disorder (RBD), in addition to neuroimaging or other biomarkers-might identify individuals in a 'pre-motor' phase of PD.
and possibly delay or prevent later complications, such as freezing phenomena or cognitive decline. Moreover, if employed prior to the early motor stage, it might be possible to delay or even prevent the onset of motor symptoms. A number of clinical trials have now been completed that have evaluated the potential for approved antiparkinsonian drugs not only to provide symptomatic relief, but also to potentially modify the disease course.
Selective Monoamine Oxidase-B Inhibitors Selegiline
As long ago as 1985, a large, uncontrolled nine-year study that simply examined the effect of adding the monoamine oxidase-B (MAO-B) inhibitor selegiline to levodopa for PD therapy showed not only amelioration of disability, but increased life expectancy in the selegiline-treated cohort. 7 Following this, the deprenyl and α-tocopherol antioxidative therapy of Parkinsonism (DATATOP) study was the first major clinical trial to attempt to ascertain whether selegiline might slow PD progression. Potential effects of α-tocopherol, a potent antioxidant, were simultaneously examined.
Eight hundred subjects with early PD were randomized to four treatment arms: selegiline/placebo; placebo/α-tocopherol; placebo/placebo; and selegiline/α-tocopherol. Selegiline, but not α-tocopherol, delayed the need for levodopa by approximately 11 months, initially raising hopes of a neuroprotective effect. 8 However, there was a clear, previously unappreciated, symptomatic benefit from selegiline apparent at one-and three-month time points. Moreover, during a washout phase, superior Unified Parkinson's Disease Rating Scale (UPDRS) 9 scores in the selegiline arm declined after two months. This symptomatic benefit meant it was not possible to attribute selegiline benefits to disease modification, as the benefit in delaying levodopa therapy could have been due to symptomatic effects.
Further studies, however, have reopened the question of whether selegiline could slow disease progression. Subjects who met the endpoint in DATATOP were allowed to enroll in an open-label extension, the BLIND-DATE study, 10 in which they received selegiline for a further 18 months and were then re-randomized to treatment with selegiline or placebo. Here, the selegiline group had a significantly lower rate of development of freezing of gait (16 % versus 29 %; p<0.0003), a significant cause of falls in advanced PD and often refractory to treatment. Additionally, a multi-step trial of selegiline in 157 individuals newly diagnosed with PD found that the rate of progression of disability, measured by UPDRS scores, was significantly slower in the selegiline cohort, and a statistically significant difference in UPDRS scores was maintained after an extended washout period. 11 These data have therefore lent support to further studies of MAO-B inhibitors.
Rasagiline
Rasagiline, like selegiline, is an irreversible and specific MAO-B inhibitor used in early and advanced PD for symptomatic benefit. Neuroprotective effects are well documented in multiple cell culture and animal models of PD. 12 The Rasagiline mesylate (TVP-1012) in early monotherapy for
Parkinson's disease outpatients (TEMPO) trial enrolled 404 subjects with early, untreated PD, who were randomized to placebo, rasagiline 1 mg daily, or rasagiline 2 mg daily. At six months, both doses of rasagiline demonstrated benefit in total UPDRS scores over placebo (-4.20 points for 1 mg rasagiline versus placebo; -3.56 points for 2 mg rasagiline versus placebo). 13 Although initiated primarily to examine symptomatic efficacy, at the end of this first six-month phase the TEMPO study became the first of two delayed-start design clinical trials implemented to specifically distinguish between symptomatic and disease-modifying effects, 14 illustrated and summarized in Figure 1 . Those taking rasagiline continued at their assigned doses, and those taking placebo were now reassigned to rasagiline 2 mg daily. 15 At the end of the second phase, i.e. after 12 months, total UPDRS score had increased (worsened) by 3.01 ± 8.26
points for the early-start 1 mg group, by 1.97 ± 7.49 points for the early-start 2 mg group, and by 4.17 ± 8.83 points for the delayed-start 2 mg group, indicating a significant advantage for early-start versus delayed-start, and providing a basis for further testing. Moreover, benefits in the early-start group appeared to be sustained. In an open-label extension of the TEMPO study, 306 subjects were followed for up to 6.5 years total, with additional antiparkinsonian medications The Attenuation of disease progression with azilect given once daily (ADAGIO) study was designed to test disease modification in a second, larger, delayed-start design trial of 1,176 patients with early, untreated PD (time since diagnosis: 4.5 ± 4.6 months). 17 For the first nine-month phase, subjects were assigned to rasagiline 1 mg or 2 mg daily or placebo. For the second nine-month phase, subjects either continued on their assigned doses of active drug, or those in the placebo arm were now assigned to rasagiline 1 or 2 mg daily. Rasagiline 1 mg daily early-start met all three of the study's hierarchical primary endpoints, when compared with rasagiline 1 mg delayed-start: (1) 
Dopamine Replacement-Levodopa
The early versus later levodopa in Parkinson's lisease (ELLDOPA) study examined efficacy over a range of doses and additionally employed a drug washout design to determine the potential effect of levodopa upon PD progression in early disease. 18 Subjects were randomized to receive placebo, 150 , 300 , or 600 mg levodopa daily over 40 weeks, at which point levodopa had a clearly superior symptomatic benefit compared with placebo, although a significant number developed motor complications even in this short trial period. A two-week drug washout period followed, at which point any symptomatic benefit was predicted to have disappeared due to the short half-life of levodopa. At the end of the washout period, despite the predicted lack of symptomatic effect, a Additionally, levodopa may have a longer-term effect on Parkinsonian symptoms than anticipated and a two-week washout period may not be long enough. Currently, use of levodopa in early PD has to be weighed against the development of motor complications, and its use is therefore delayed in many patients.
Dopamine Agonists
The dopamine agonists bromocriptine, pergolide (no longer used), ropinirole, pramipexole, and rotigotine (unavailable in the US at the time of writing) have all demonstrated efficacy in treating motor symptoms and activities of daily living (ADL) in PD (see Table 1 ). An apparent advantage for the management of motor symptoms of PD is that these medications lead to fewer motor complications than levodopa. For example, in a study comparing pramipexole to levodopa treatment, 19 those assigned to initial pramipexole experienced significantly less wearing off and fewer dyskinesias or on-off motor fluctuations (28 %), compared with those assigned to initial levodopa (51 %).
Two clinical trials in early motor PD, using ropinirole and pramipexole, have examined the effects of treatment upon neuroimaging measures of PD progression. Pramipexole has neuroprotective properties in preclinical studies. 20 The p=0.022). 22 While further studies are needed to determine precisely how to interpret neuroimaging results, the delay in developing motor complications favors the use of dopamine agonists over levodopa in early motor PD, unless adverse effects rule otherwise. However, with the lack of a placebo group in either the CALM-PD or REAL-PET trials, it is unclear whether dopamine agonists might have benefit for PD progression, and therefore whether they would be helpful in the pre-motor phase. In an attempt to answer this question, the Pramipexole on underlying disease (PROUD) study evaluated pramipexole for a potential disease-modifying effect using a delayed-start study design. 23 Unfortunately, results did not support a disease-modifying benefit of a 1.5 mg dose of pramipexole, 24 and use of these drugs in early motor PD therefore remains based upon symptomatic motor benefits.
Agents that Modulate Glutamate Activity
Amantadine is used for therapeutic benefit in early and advanced motor PD and its use has been associated in one study with improved 10-year survival rates. 25 This is interesting, since a modified form of acute excitotoxic injury, 'weak excitotoxicity', involving calcium influx via NMDA receptor channels, has been proposed as a potential mechanism of cell injury and cell loss in PD. 26 This suggests that agents directly acting at the NMDA receptor, such as amantadine, or, alternatively, interventions that indirectly modulate glutamate activity, might slow disease progression. At this time, however, there are no clinical data to support the use of anti-excitotoxic agents for the purpose of neuroprotection in PD. Amantadine has not been evaluated specifically for disease progression effects, and nor has the related glutamatergic agent memantine. A two-year placebo-controlled, double-blind, multi-center trial of riluzole, approved for use in amyotrophic lateral sclerosis, in 1,084 PD subjects was terminated early after meeting predefined criteria for futility. 27 Attention is now turning to other glutamate receptors, notably the AMPA receptor, and the metabotropic glutamate receptors (mGluRs), with promise for both symptomatic and disease-modifying effects in preclinical studies. 28 
New Developments in Parkinson's Disease Therapeutics
New targets are being addressed in drug development including α2-adrenergic receptors, adenosine A2a receptors, and agents with multiple modes of action including safinamide, which is a reversible MAO-B inhibitor, reduces dopamine re-uptake, and has antiglutamatergic effects, 29 and piribedil, a partial dopamine receptor D2/D3 agonist and α2-adrenergic receptor antagonist. 30 As yet, there are no clinical data supporting their potential use as disease-modifying drugs.
Ongoing Clinical Trials Examining Disease Modification
A novel, orally active, small molecule, PYM50028 (Cogane), is currently being tested in a Phase II trial in early motor PD (CONFIDENT-PD: NCT01060878). This agent has both neuroprotective and neurorestorative iproperties in preclinical studies and, in one study in 1-methyl-4-phenyl- 33, 34 Creatine, a nutritional supplement that plays an important role in mitochondrial energy production, was found to be non-futile in a double-blind, futility clinical trial of creatine and minocycline in early PD. 35 It is now being investigated in the NET-PD LS-1 study, in which 1,720 participants will be randomly assigned to receive either creatine or a placebo for a minimum of five years (NCT00449865). It is too early to determine how these interventions may be applied to early motor PD, and especially pre-motor PD; such approaches are beyond the scope of this article and have been discussed elsewhere. domains not previously emphasized. 42 Other rating scales are employed for better evaluation of non-motor features that may occur in PD at various stages; for example, the benefit of rasagiline versus placebo for relief of fatigue was specifically addressed in the ADAGIO trial. 42 The Quality Standards Subcommittee of the American Academy of Neurology published a systematic review on screening tools for psychosis, dementia, and depression in PD, 43 and certain studies have 
Conclusions
The recognition of a pre-motor phase, and possibly earlier stages of As agents become available that have disease-modifying effects in diagnosed PD, is it reasonable to 'move earlier': to employ them in the pre-motor phase or in even earlier stages of PD? A major, and as yet unanswered, question is how to ascertain the health-related advantages of such an approach, given that at present there is not even a validated marker of disease progression in motor PD. Drug interventions in early stages will increase initial healthcare costs, and, with the incidence of PD increasing worldwide, the impact of early treatment strategies will need to be analyzed in economic terms. 47 The advantage of delaying therapy could be to reduce initial costs, but might there be a missed opportunity to improve prognosis, and thereby decrease health-related, social, and economic burdens?
Finally, there are valuable lessons to be learned from extensive experience in other disorders, such as vascular disease, in which lifestyle is shown to play an important role. There is increasing evidence that diet may modify PD risk. For example, in the Health professionals follow-up study and the Nurses' health study, individuals who followed a so-called 'prudent' dietary pattern, with high intake of fruit, vegetables, legumes, whole grains, nuts, fish, and poultry, low intake of saturated fat, and moderate intake of alcohol, were at less risk of developing PD. 48 In the National Institutes of Health-American Association of retired persons (NIH-AARP) diet and health study cohort, higher levels of moderate to vigorous exercise were associated with a lower risk of developing PD. 49 Other modifiable factors, such as hypertension in women, have been linked to PD risk. 50 Environmental risks are also a potential target for modification, as pesticide exposure has now been linked to PD risk in multiple studies. 51 These studies, as well as research efforts to identify neuroprotective agents, underscore the possibility of a shift in thinking from symptomatic treatment to disease modification and eventually prevention. n
